Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

CorMedix Inc., a biopharmaceutical company, focuses on developing and commercializing therapeutic products for the prevention and treatment of infectious and inflammatory diseases in the United States and internationally. Its lead product candidate is DefenCath/Neutrolin, a novel anti-infective solution for the reduction and prevention of catheter-related infections and thrombosis in patients requiring central venous catheters in clinical settings, such as hemodialysis, total parenteral nutrition, and oncology. The company was formerly known as Picton Holding Company, Inc. and changed its name to CorMedix, Inc. in January 2007. CorMedix Inc. was incorporated in 2006 and is based in Berkeley Heights, New Jersey.

CorMedix Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

- ENROLLMENT COMPLETED IN ONGOING PHASE III RESPECT STUDY IN PROPHYLAXIS OF FUNGAL INFECTIONS IN ADULT PATIENTS UNDERGOING ALLOGENEIC BLOOD AND MARROW TRANSPLANT -

CORMEDIX ANNOUNCES COMPLETION OF ENROLLMENT IN PHASE III RESPECT CLINICAL TRIAL FOR REZZAYO

BERKELEY HEIGHTS, N.J., SEPT. 08, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (CORMEDIX) (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED THAT IT HAS MADE A $5 MILLION STRATEGIC MINORITY EQUITY INVESTMENT IN TALPHERA, INC. (NASDAQ: TLPH), ACQUIRING 9,090,909 SHARES AT AN AT-MARKET PRICE OF $0.55 PER SHARE AS PART OF TALPHERA'S CONCURRENTLY ANNOUNCED PRIVATE PLACEMENT FINANCING.

CORMEDIX ANNOUNCES STRATEGIC MINORITY INVESTMENT IN TALPHERA

CORMEDIX IS MAKING A STRATEGIC INVESTMENT IN TALPHERA AS THE LEAD INVESTOR, SUPPORTED BY EXISTING STOCKHOLDERS NANTAHALA, ROSALIND AND ROCK SPRINGS WITH SEVERAL NEW INSTITUTIONAL INVESTORS $17 MILLION IN PROCEEDS AT FIRST CLOSING WITH THE POTENTIAL TO RECEIVE AN ADDITIONAL $12 MILLION ACROSS ONE ADDITIONAL TRANCHE UPON THE ACHIEVEMENT OF THE PRIMARY ENDPOINT IN THE NEPHRO CLINICAL STUDY THE COMPLETION OF THIS FINANCING IS EXPECTED TO PROVIDE THE COMPANY WITH SUFFICIENT CAPITAL THROUGH THE PLANNED APPROVAL OF A NIYAD PMA IN THE SECOND HALF OF 2026 SAN MATEO, CALIF. , SEPT. 8, 2025 /PRNEWSWIRE/ --TALPHERA, INC.(NASDAQ: TLPH), (TALPHERA), A SPECIALTY PHARMACEUTICAL COMPANY FOCUSED ON THE DEVELOPMENT AND COMMERCIALIZATION OF INNOVATIVE THERAPIES FOR USE IN MEDICALLY SUPERVISED SETTINGS, TODAY ANNOUNCED IT HAS ENTERED INTO SECURITIES PURCHASE AGREEMENTS WITH CORMEDIX INC. AND CERTAIN INSTITUTIONAL INVESTORS FOR THE SALE AND ISSUANCE OF SHARES OF COMMON STOCK AND PRE-FUNDED WARRANTS IN LIEU OF SHARES TO PURCHASE COMMON STOCK IN A PRIVATE PLACEMENT FOR TOTAL POTENTIAL PROCEEDS OF UP TO $29 MILLION.

TALPHERA ANNOUNCES PRIVATE PLACEMENT FINANCING OF UP TO $29 MILLION PRICED AT-THE MARKET

- TRANSFORMATIONAL DEAL FOR CORMEDIX THAT EXPANDS AND DIVERSIFIES COMPANY'S COMMERCIAL PRODUCT PORTFOLIO, WITH SEVEN INNOVATIVE DRUG PRODUCTS AND A PIPELINE EXPANSION INDICATION WITH NEAR-TERM REVENUE GROWTH POTENTIAL -

CORMEDIX COMPLETES ACQUISITION OF MELINTA THERAPEUTICS, RAISES FINANCIAL GUIDANCE AND ANNOUNCES NEW LEADERSHIP TEAM

BERKELEY HEIGHTS, N.J., AUG. 28, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (CORMEDIX) (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED THAT SENIOR MANAGEMENT WILL BE PRESENTING AND PARTICIPATING IN INVESTOR MEETINGS AT UPCOMING INVESTOR CONFERENCES TAKING PLACE IN SEPTEMBER.

CORMEDIX TO PARTICIPATE IN UPCOMING INVESTOR CONFERENCES

PARSIPPANY, N.J.--(BUSINESS WIRE)--MELINTA THERAPEUTICS ANNOUNCES STRATEGIC ACQUISITION BY CORMEDIX, UNDERSCORING ITS PORTFOLIO VALUE AND INDUSTRY LEADERSHIP.

MELINTA THERAPEUTICS ANNOUNCES STRATEGIC ACQUISITION BY CORMEDIX, UNDERSCORING ITS PORTFOLIO VALUE AND INDUSTRY LEADERSHIP

TRANSFORMATIONAL DEAL FOR CORMEDIX THAT EXPANDS AND DIVERSIFIES COMPANY'S COMMERCIAL PRODUCT PORTFOLIO, WITH SEVEN INNOVATIVE DRUG PRODUCTS AND A PIPELINE EXPANSION INDICATION WITH NEAR-TERM REVENUE GROWTH POTENTIAL TRANSACTION EXPECTED TO BE NEAR-TERM ACCRETIVE TO EPS WITH DOUBLE-DIGIT ACCRETION EXPECTED IN 2026; ANNUAL RUN-RATE SYNERGIES EXPECTED TO BE ~$35 TO $45 MILLION PRO FORMA 2025 COMBINED REVENUES ESTIMATED TO BE $305 TO $335 MILLION ADVANCES CORMEDIX'S STRATEGY TO BUILD A FORMIDABLE SPECIALTY PHARMACEUTICAL BUSINESS THROUGH A COMBINATION OF ORGANIC AND INORGANIC GROWTH DYNAMIC PLATFORM CAN BE LEVERAGED TO SUPPORT ADDITIONAL PRODUCTS AND EXPAND AS THE COMBINED COMPANY ENTERS ITS NEXT PHASE CORMEDIX TO HOST CONFERENCE CALL AND WEBCAST TODAY AT 8:30 A.M. ET. BERKELEY HEIGHTS, N.J.

CORMEDIX TO ACQUIRE MELINTA THERAPEUTICS, CREATING DIVERSIFIED SPECIALTY COMPANY WITH STRONG PRESENCE IN ACUTE CARE SETTINGS

 Q2 2025 NET REVENUE OF $39.7MM; NET INCOME OF $19.8MM; ADJUSTED EBITDA OF $22.4MM   COMPANY ANNOUNCES ACQUISITION OF MELINTA THERAPEUTICS   CONFERENCE CALL SCHEDULED FOR TODAY AT 8:30 A.M. EASTERN TIME  BERKELEY HEIGHTS, N.J.

CORMEDIX INC. REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE

BERKELEY HEIGHTS, N.J., JUNE 27, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED THE PRICING OF ITS PREVIOUSLY ANNOUNCED UNDERWRITTEN PUBLIC OFFERING OF 6,604,507 SHARES OF ITS COMMON STOCK. THE TOTAL GROSS PROCEEDS FROM THE OFFERING TO THE COMPANY ARE EXPECTED TO BE APPROXIMATELY $85 MILLION. IN ADDITION, CORMEDIX GRANTED THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF ITS COMMON STOCK OFFERED IN THE OFFERING. THE CLOSING OF THE OFFERING IS EXPECTED TO OCCUR ON OR ABOUT JUNE 30, 2025, SUBJECT TO THE SATISFACTION OF CUSTOMARY CLOSING CONDITIONS.

CORMEDIX INC. ANNOUNCES PRICING OF PUBLIC OFFERING OF COMMON STOCK

BERKELEY HEIGHTS, N.J., JUNE 26, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCED THAT IT INTENDS TO OFFER AND SELL $85.0 MILLION OF SHARES OF ITS COMMON STOCK IN AN UNDERWRITTEN PUBLIC OFFERING. ALL OF THE SHARES TO BE SOLD IN THE OFFERING WILL BE OFFERED BY CORMEDIX. IN ADDITION, CORMEDIX INTENDS TO GRANT THE UNDERWRITERS A 30-DAY OPTION TO PURCHASE UP TO AN ADDITIONAL 15% OF THE SHARES OF ITS COMMON STOCK OFFERED IN THE PUBLIC OFFERING, AT THE PUBLIC OFFERING PRICE, LESS UNDERWRITING DISCOUNTS AND COMMISSIONS. THE OFFERING IS SUBJECT TO MARKET CONDITIONS, AND THERE CAN BE NO ASSURANCE AS TO WHETHER OR WHEN THE OFFERING MAY BE COMPLETED, OR AS TO THE ACTUAL SIZE OR TERMS OF THE OFFERING.

CORMEDIX INC. ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

BERKELEY HEIGHTS, N.J., JUNE 23, 2025 (GLOBE NEWSWIRE) -- CORMEDIX INC. (NASDAQ: CRMD), A BIOPHARMACEUTICAL COMPANY FOCUSED ON DEVELOPING AND COMMERCIALIZING THERAPEUTIC PRODUCTS FOR LIFE-THREATENING DISEASES AND CONDITIONS, TODAY ANNOUNCES AN UPDATE RELATED TO ITS LARGE DIALYSIS ORGANIZATION (LDO) CUSTOMER AND PLANNED IMPLEMENTATION IN THE SECOND HALF OF 2025.

CorMedix Inc.

CRMD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CorMedix Inc.

CRMD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

CRMD